Roche Holding AG

Drug Name	Phase	Indication	Designations	Patent
Ranibizumab	Phase 3	Diabetic Macular Edema	-	-
Antipsychotics	Phase 3	Schizophrenia	-	-
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg	Phase 3	Hepatitis B, Chronic	-	-
Cladribine	Phase 3	Lymphocytic Leukemia, Chronic	-	-
Dacarbazine	Phase 3	Malignant Melanoma	-	-
Emicizumab	Phase 3	Hemophilia A	-	-
rFVIIa	Phase 3	Hemophilia A	-	-
metformin	Phase 3	Diabetes Mellitus Type 2	-	-
Taxotere	Phase 3	Breast Cancer	-	-
ibandronate [Bonviva/Boniva]	Phase 3	Post-Menopausal Osteopenia	-	-
Trontinemab	Phase 3	Alzheimers Disease	-	-
Fluoropyrimidine-based Chemotherapy	Phase 3	Colorectal Cancer	-	-
Afimkibart	Phase 3	Crohns Disease	-	-
CDK4/6i	Phase 3	Breast Cancer	-	-
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab	Phase 3	Diabetic Retinopathy	-	-
Aflibercept	Phase 3	Diabetic Macular Edema	-	-
CMF	Phase 3	Breast Cancer	-	-
Doxorubicin	Phase 3	Diffuse Large B-Cell Lymphoma, Lymphoma Follicular	-	-
Stavudine	Phase 3	HIV Infections	-	-
Paclitaxel	Phase 3	Ovarian Cancer	-	-
Docetaxel	Phase 3	Non-Small Cell Lung Cancer	-	-
tocilizumab [RoActemra/Actemra]	Phase 3	Rheumatoid Arthritis	-	-
temozolomide	Phase 3	Glioblastoma Multiforme	-	-
Ganciclovir	Phase 3	Cytomegalovirus Retinitis	-	-
tocilizumab SC	Phase 3	Rheumatoid Arthritis	-	-
Lamivudine	Phase 3	HIV Infections	-	-
PDS Implant with Ranibizumab 100 mg/mL	Phase 3	Neovascular Age-Related Macular Degeneration	-	-
Erlotinib	Phase 3	Non-Squamous Non-Small Cell Lung Cancer	-	-
satralizumab	Phase 3	Neuromyelitis Optica Spectrum Disorder	-	-
MMF	Phase 3	Lupus Nephritis	-	-
Trastuzumab	Phase 3	Breast Cancer	-	-
Rituximab	Phase 3	Rheumatoid Arthritis	-	-
Sitagliptin	Phase 3	Diabetes Mellitus Type 2	-	-
interferon-a-2a	Phase 3	Lymphoma	-	-
Baloxavir Marboxil	Phase 3	Influenza	-	-
TRO19622	Phase 3	Amyotrophic Lateral Sclerosis	-	-
XELOX	Phase 3	Colorectal Cancer	-	-
aleglitazar	Phase 3	Diabetes Mellitus Type 2	-	-
Standard adjuvant chemotherapy	Phase 3	Breast Cancer	-	-
DMARD	Phase 3	Rheumatoid Arthritis	-	-
Sunitinib	Phase 3	Renal Cell Carcinoma	-	-
Atezolizumab	Phase 3	Carcinoma, Hepatocellular	-	-
Mycophenolate Mofetil 2 g/Day	Phase 3	Pemphigus Vulgaris (PV)	-	-
Alectnib	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Lebrikizumab	Phase 3	Asthma	-	-
Faricimab	Phase 3	Wet Macular Degeneration	-	-
Pegylated-interferon Alfa-2a	Phase 3	Hepatitis C, Chronic	-	-
Standard chemotherapy	Phase 3	Breast Cancer	-	-
von Willebrand Factor (VWF) Concentrates	Phase 3	Von Willebrand Disease, Type 3	-	-
Oral Corticosteroids	Phase 3	Rheumatoid Arthritis	-	-
Chemotherapy	Phase 3	Non-Small Cell Lung Cancer	-	-
Prednisone	Phase 3	Lymphoma	-	-
Inavolisib	Phase 3	Breast Cancer	-	-
Leucovorin (LV)	Phase 3	Colorectal Cancer	-	-
valganciclovir [Valcyte]	Phase 3	Cytomegalovirus Infections	-	-
CHOP	Phase 3	Lymphoma, Large B-Cell, Diffuse	-	-
Acetaminophen/ Paracetamol	Phase 3	Childhood Idiopathic Nephrotic Syndrome	-	-
rituximab [MabThera]	Phase 3	Rheumatoid Arthritis	-	-
RO4917838	Phase 3	Schizophrenia	-	-
Corticosteroids	Phase 3	Breast Cancer	-	-
Antihistamine	Phase 3	Multiple Sclerosis	-	-
Lapatinib	Phase 3	Breast Cancer	-	-
epoetin	Phase 3	Anemia	-	-
Baseline Treatment	Phase 3	Neuromyelitis Optica (NMO)	-	-
Human Coagulation Factor VIII	Phase 3	Hemophilia A	-	-
Nab-paclitaxel	Phase 3	Non-Small-Cell Lung	-	-
Acetaminophen/Paracetamol	Phase 3	Systemic Lupus Erythematosus	-	-
fusidic acid [Verutex]	Phase 3	Non-Small Cell Lung Cancer	-	-
Phesgo	Phase 3	Locally Advanced or Metastatic Breast Cancer	-	-
Oxaliplatin	Phase 3	Colorectal Cancer	-	-
Risdiplam	Phase 3	Muscular Atrophy, Spinal	-	-
Fludarabine Phosphate	Phase 3	Chronic Lymphocytic Leukemia	-	-
Ocrelizumab	Phase 3	Multiple Sclerosis	-	-
Pegylated Interferon (PEG-IFN) alfa-2a	Phase 3	Hepatitis D, Chronic	-	-
Enzalutamide	Phase 3	Prostatic Neoplasms, Castration-Resistant	-	-
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)	Phase 3	Anemia	-	-
RO7204239	Phase 3	Obesity	-	-
Mircera	Phase 3	Anemia	-	-
oseltamivir	Phase 3	Influenza, Human	-	-
Gemcitabine (Chemotherapy)	Phase 3	Ovarian Cancer	-	-
erlotinib [Tarceva]	Phase 3	Non-Small Cell Lung Cancer	-	-
methoxy polyethylene glycol-epoetin beta [C.E.R.A.]	Phase 3	Anemia	-	-
Saquinavir	Phase 3	HIV Infections	-	-
Second-Line Chemotherapy	Phase 3	Non-Squamous Non-Small Cell Lung Cancer	-	-
Nelfinavir mesylate	Phase 3	HIV Infections	-	-
Pemetrexed	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Zalcitabine	Phase 3	HIV Infections	-	-
Ortho-Novum® 1/35	Phase 3	Rheumatoid Arthritis	-	-
Efavirenz	Phase 3	HIV Infections	-	-
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody	Phase 3	Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer	-	-
Cevostamab	Phase 3	Multiple Myeloma	-	-
Obinutuzumab	Phase 3	Chronic Lymphocytic Leukemia (CLL)	-	-
Etrozulimab	Phase 3	Ulcerative Colitis	-	-
Vinflunine	Phase 3	Bladder Cancer	-	-
PEGASYS	Phase 3	Hepatitis C, Chronic	-	-
Neoral	Phase 3	Kidney Transplantation	-	-
Gantenerumab	Phase 3	Alzheimer's Disease	-	-
PDS Implant filled with 100 mg/mL Ranibizumab	Phase 3	Neovascular Age-Related Macular Degeneration	-	-
Fulvestrant	Phase 3	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	-	-
anti-IL-2R	Phase 3	Kidney Transplantation	-	-
Cisplatin	Phase 3	Nasopharyngeal Cancer	-	-
Endocrine Therapy of Physician's Choice	Phase 3	Early Breast Cancer	-	-
RO7771950	Phase 3	HER2-positive Breast Cancer	-	-
orlistat [Xenical]	Phase 3	Obesity	-	-
rituximab [MabThera/Rituxan]	Phase 3	Rheumatoid Arthritis	-	-
montelukast [Singulair]	Phase 3	Asthma	-	-
Delavirdine mesylate	Phase 3	HIV Infections	-	-
adefovir dipivoxil	Phase 3	Hepatitis B, Chronic	-	-
aleglitazar+metformin	Phase 3	Diabetes Mellitus Type 2	-	-
Chemotherapy (Induction Period)	Phase 3	Non-Hodgkin's Lymphoma	-	-
Fludarabine	Phase 3	Lymphocytic Leukemia, Chronic	-	-
tenofovir	Phase 3	Hepatitis D, Chronic	-	-
RO7239361	Phase 3	Duchenne Muscular Dystrophy	-	-
Cyclophosphamide	Phase 3	Breast Cancer	-	-
RO0503821 (1x/2 Weeks)	Phase 3	Anemia	-	-
dalcetrapib	Phase 3	Coronary Heart Disease	-	-
pioglitazone	Phase 3	Diabetes Mellitus Type 2	-	-
Olesoxime	Phase 3	Muscular Atrophy, Spinal	-	-
Riluzole	Phase 3	Amyotrophic Lateral Sclerosis	-	-
Astegolimab	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Vinorelbine	Phase 3	Non-Small Cell Lung Cancer	-	-
liposomal doxorubicin	Phase 3	Ovarian Cancer	-	-
Omalizumab	Phase 3	Nasal Polyps	-	-
Non-Biologic DMARDs	Phase 3	Rheumatoid Arthritis	-	-
bitopertin [RO4917838]	Phase 3	Schizophrenia	-	-
Palbociclib	Phase 3	Breast Cancer	-	-
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody	Phase 3	Squamous Non-Small Cell Lung Cancer	-	-
Mycophenolate mofetil (MMF)	Phase 3	Lupus Nephritis	-	-
5-Fluorouracil	Phase 3	Gastric Cancer	-	-
cyclosporine A (CsA)	Phase 3	Heart Transplantation	-	-
Tiragolumab and Atezolizumab	Phase 3	Cancer	-	-
Cobimetinib	Phase 3	Melanoma	-	-
Bendamustine	Phase 3	Chronic Lymphocytic Leukemia	-	-
Platinum chemotherapy (cisplatin or carboplatin)	Phase 3	Non-Squamous Non-Small Cell Lung Cancer	-	-
Irinotecan	Phase 3	Colorectal Cancer	-	-
Pertuzumab IV	Phase 3	Early Breast Cancer	-	-
csDMARDs	Phase 3	Rheumatoid Arthritis	-	-
Venetoclax	Phase 3	Chronic Lymphocytic Leukemia	-	-
DMARDs	Phase 3	Rheumatoid Arthritis	-	-
MabThera/Rituxan	Phase 3	Rheumatoid Arthritis	-	-
Pomalidomide	Phase 3	Multiple Myeloma	-	-
RO7234292	Phase 3	Huntingtons Disease	-	-
Onartuzumab [MetMAb]	Phase 3	Non-Small Cell Lung Cancer	-	-
RO7234292 (RG6042)	Phase 3	Huntington Disease	-	-
Epirubicin	Phase 3	Breast Cancer	-	-
epoetin beta [NeoRecormon]	Phase 3	Anemia	-	-
Regorafenib	Phase 3	Colorectal Cancer	-	-
Tacrolimus	Phase 3	Primary Membranous Nephropathy	-	-
pertuzumab [Perjeta]	Phase 3	Breast Cancer	-	-
trastuzumab [Herceptin]	Phase 3	Breast Cancer	-	-
Acitretin	Phase 3	HIV Infections	-	-
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)	Phase 3	Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma	-	-
Ranibizumab (10 mg/mL)	Phase 3	Neovascular Age-related Macular Degeneration	-	-
Crovalimab	Phase 3	Atypical Hemolytic Uremic Syndrome	-	-
insulin glargine	Phase 3	Diabetes Mellitus Type 2	-	-
Lenalidomide	Phase 3	Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma	-	-
Entecavir	Phase 3	Pediatric Immuno-Tolerant Chronic Hepatitis B	-	-
Mosunetuzumab	Phase 3	Non-Hodgkin Lymphoma	-	-
tocilizumab	Phase 3	Rheumatoid Arthritis	-	-
Nonbiologic DMARDs of investigator's choice	Phase 3	Rheumatoid Arthritis	-	-
Prasinezumab	Phase 3	Parkinsons Disease	-	-
Tocilizumab 162 mg	Phase 3	Rheumatoid Arthritis	-	-
Optional Endocrine Therapy of Investigator's Choice	Phase 3	Metastatic Breast Cancer	-	-
bevacizumab [Avastin]	Phase 3	Non-Squamous Non-Small Cell Lung Cancer	-	-
ritonavir	Phase 3	HIV Infections	-	-
Epoetin alfa	Phase 3	Anemia	-	-
5-Fluorouracil (5-FU)	Phase 3	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	-	-
Leucovorin calcium	Phase 3	Colorectal Cancer	-	-
Etrolizumab	Phase 3	Crohn Disease	-	-
leucovorin	Phase 3	Colorectal Cancer	-	-
Epoetin beta	Phase 3	Anemia	-	-
Lurbinectedin	Phase 3	Small-Cell Lung Cancer	-	-
Dalcetrapib (RO4607381)	Phase 3	Coronary Heart Disease	-	-
taspoglutide	Phase 3	Diabetes Mellitus Type 2	-	-
FEC Chemotherapy	Phase 3	Breast Cancer	-	-
Bevacizumab	Phase 3	Carcinoma, Hepatocellular	-	-
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody	Phase 3	Triple-Negative Breast Cancer	-	-
Ibandronate	Phase 3	Post-Menopausal Osteoporosis	-	-
methotrexate	Phase 3	Rheumatoid Arthritis	-	-
Entrectinib	Phase 3	Solid Tumors	-	-
Darbepoetin alfa	Phase 3	Anemia	-	-
Interferon beta-1a	Phase 3	Relapsing Multiple Sclerosis	-	-
Carboplatin	Phase 3	Breast Cancer	-	-
Etoposide	Phase 3	Small Cell Lung Carcinoma	-	-
Mycophenolate Mofetil	Phase 3	Pemphigus Vulgaris	-	-
Folic acid or folate	Phase 3	Rheumatoid Arthritis	-	-
Evidence-based medical care for Acute Coronary Syndrome	Phase 3	Coronary Heart Disease	-	-
Vincristine	Phase 3	Non-Hodgkin's Lymphoma	-	-
peginterferon alfa-2a [Pegasys]	Phase 3	Hepatitis B, Chronic	-	-
Tiragolumab	Phase 3	Small Cell Lung Cancer	-	-
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]	Phase 3	Anemia	-	-
methylprednisolone	Phase 3	Rheumatoid Arthritis	-	-
Vamikibart	Phase 3	Diabetic Macular Edema	-	-
Ribavirin	Phase 3	Hepatitis C, Chronic	-	-
Factor VIII (FVIII)	Phase 3	Hemophilia A	-	-
Methoxy Polyethylene Glycol-Epoetin Beta	Phase 3	Anemia	-	-
Pralsetinib	Phase 3	RET-fusion Non Small Cell Lung Cancer	-	-
Cabozantinib	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Anti-VEGF Therapy	Phase 3	Neovascular Age-related Macular Degeneration	-	-
rHuPH20	Phase 3	Non-Small Cell Lung Cancer	-	-
mycophenolate mofetil (CellCept)	Phase 3	Myasthenia Gravis, Generalized	-	-
epoetin alfa or beta	Phase 3	Anemia	-	-
Tociluzumab	Phase 3	Relapsed or Refractory Follicular Lymphoma	-	-
Zidovudine	Phase 3	HIV Infections	-	-
Remdesivir	Phase 3	COVID-19 Pneumonia	-	-
Polatuzumab Vedotin	Phase 3	Non-Hodgkin's Lymphoma	-	-
r-HuEPO	Phase 3	Anemia	-	-
Fingolimod	Phase 3	Relapsing-Remitting Multiple Sclerosis	-	-
Teriflunomide	Phase 3	Relapsing Multiple Sclerosis	-	-
Sefaxersen (RO7434656)	Phase 3	Primary IgA Nephropathy	-	-
trastuzumab (Herceptin®)	Phase 3	Breast Cancer	-	-
Onartuzumab	Phase 3	Glioblastoma	-	-
tocilizumab [RoActemra]	Phase 3	Rheumatoid Arthritis	-	-
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)	Phase 3	Rheumatoid Arthritis	-	-
Pirfenidone	Phase 3	Lung Diseases, Interstitial	-	-
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody	Phase 3	Carcinoma, Non-Squamous Non-Small Cell Lung	-	-
Capecitabine	Phase 3	Gastric Cancer	-	-
Tocilizumab (TCZ)	Phase 3	Rheumatoid Arthritis	-	-
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)	Phase 3	Early Breast Cancer	-	-
Valganciclovir CMV Prophylaxis	Phase 3	Cytomegalovirus Infections	-	-
Trastuzumab IV	Phase 3	HER2-positive Early Breast Cancer	-	-
Other Combination Anti-Cancer Therapies	Phase 3	Solid Tumors	-	-
Neo-adjuvant chemotherapy	Phase 3	Breast Cancer	-	-
5 FU	Phase 3	Neoplasms	-	-
Enfuvirtide	Phase 3	HIV Infections	-	-
Pertuzumab	Phase 3	Breast Cancer	-	-
Taxane-based chemotherapy	Phase 3	Breast Cancer	-	-
mycophenolate mofetil [CellCept]	Phase 3	Myasthenia Gravis Generalised	-	-
Cyclosporine	Phase 3	Renal Transplantation	-	-
23-PPV	Phase 3	Multiple Sclerosis, Relapsing-Remitting	-	-
FAP IL2V	Phase 3	Cancer	-	-
Alimta or Taxotere	Phase 3	Non-Small Cell Lung Cancer	-	-
Lenvatinib	Phase 3	Unresectable Hepatocellular Carcinoma	-	-
Oxaliplatin 130 mg/m^2	Phase 3	Colorectal Cancer	-	-
Non-steroidal anti-inflammatory drugs (NSAIDs)	Phase 3	Juvenile Idiopathic Arthritis	-	-
chlorambucil	Phase 3	Lymphocytic Leukemia, Chronic	-	-
5-Fluoruracil	Phase 3	Gastric Cancer	-	-
Giredestrant	Phase 3	Endometrial Cancer	-	-
Oseltamivir IV	Phase 3	Influenza	-	-
Sorafenib	Phase 3	Carcinoma, Hepatocellular	-	-
Eculizumab	Phase 3	Paroxysmal Nocturnal Hemoglobinuria	-	-
Interferon alfa 2a [Roferon]	Phase 3	Renal Cell Cancer	-	-
Disease-modifying anti-rheumatic drugs	Phase 3	Rheumatoid Arthritis	-	-
Becavizumab	Phase 3	Hepatocellular Carcinoma	-	-
Valganciclovir	Phase 3	Cytomegalovirus Infections	-	-
Filgrastim	Phase 3	Triple-negative Breast Cancer	-	-
Azathioprine	Phase 3	Rheumatoid Arthritis	-	-
Letrozole	Phase 3	Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	-	-
methoxy polyethylene glycol-epoetin beta [Mircera]	Phase 3	Anemia	-	-
Herceptin	Phase 3	Breast Cancer	-	-
Infliximab	Phase 3	Ulcerative Colitis	-	-
Crizotinib	Phase 3	Neoplasms	-	-
Intravitreal Ranibizumab 0.5 mg Injection	Phase 3	Diabetic Macular Edema	-	-
Fluorouracil	Phase 3	Gastric Cancer	-	-
Bitopertin	Phase 3	Beta-Thalassemia	-	-
Pegylated Interferon Alfa-2a	Phase 3	Chronic Myelogenous Leukemia	-	-
Pembrolizumab	Phase 3	Non-small Cell Lung Cancer (NSCLC)	-	-
Vemurafenib	Phase 3	Melanoma	-	-
Divarasib	Phase 3	Non-Small Cell Lung Cancer	-	-
Rituximab SC	Phase 3	Non-Hodgkin's Lymphoma	-	-
Trastuzumab Emtansine	Phase 3	Breast Cancer	-	-
Gemcitabine	Phase 3	Pancreatic Cancer	-	-
Fenebrutinib	Phase 3	Relapsing Multiple Sclerosis	-	-
Treatment of physician's choice	Phase 3	Breast Cancer	-	-
saquinavir [Invirase]	Phase 3	HIV Infections	-	-
Optimized background antiretroviral regimen (OB)	Phase 3	HIV Infections	-	-
Dexamethasone	Phase 3	Idiopathic Thrombocytopenic Purpura	-	-
Permitted DMARDs	Phase 3	Rheumatoid Arthritis	-	-
Adalimumab	Phase 3	Ulcerative Colitis	-	-
exenatide	Phase 3	Diabetes Mellitus Type 2	-	-
Ocrelizumab IV	Phase 3	Relapsing Multiple Sclerosis	-	-
Glofitamab	Phase 3	Diffuse Large B-cell Lymphoma	-	-
bitopertin [RO4917838] level 1	Phase 3	Schizophrenia	-	-
MTX	Phase 3	Rheumatoid Arthritis	-	-
Alectinib	Phase 3	Non-Small Cell Lung Cancer	-	-
Ipatasertib	Phase 3	Triple-Negative Breast Cancer	-	-
capecitabine [Xeloda]	Phase 3	Colorectal Cancer	-	-
Peginterferon alfa-2a	Phase 3	Carcinoma, Hepatocellular	-	-
Olaparib	Phase 2	Cancer of Unknown Primary Site	-	-
Dual Integrin Antagonist	Phase 2	Asthma	-	-
RO4917523 1.5 mg	Phase 2	Major Depressive Disorder	-	-
Atezolizumab Cohort 7	Phase 2	Solid Tumors	-	-
boceprevir	Phase 2	Hepatitis C, Chronic	-	-
Abemaciclib	Phase 2	Ovarian Cancer	-	-
Ro 24-7429	Phase 2	Sarcoma, Kaposi	-	-
antibody induction	Phase 2	Kidney Transplantation	-	-
Onartuzumab (MetMAb)	Phase 2	Gastric Cancer	-	-
Standard antipsychotic therapy	Phase 2	Schizophrenia	-	-
RO6864018	Phase 2	Hepatitis B, Chronic	-	-
RO5093151	Phase 2	Hypertension, Glaucoma, Open-Angle	-	-
RO7268489	Phase 2	Progressive Multiple Sclerosis	-	-
RO4588161	Phase 2	Hepatitis C, Chronic	-	-
Mericitabine	Phase 2	Hepatitis C	-	-
Induction Chemotherapy	Phase 2	Breast Cancer	-	-
Actos	Phase 2	Diabetes Mellitus Type 2	-	-
Erythropoietin Beta	Phase 2	Myelodysplastic Syndromes	-	-
Doxycline	Phase 2	Non-Small Cell Lung Cancer	-	-
obinutuzumab (RO5072759)	Phase 2	Non-Hodgkin's Lymphoma	-	-
Iberdomide	Phase 2	Multiple Myeloma	-	-
ibandronate [Bondronat]	Phase 2	Pain; Bone Neoplasms; Neoplasm Metastasis	-	-
Mosunetuzumab (SC)	Phase 2	Follicular Lymphoma	-	-
RO4876904	Phase 2	Diabetes Mellitus Type 2	-	-
Crenezumab	Phase 2	Alzheimer Disease	-	-
ANA598	Phase 2	HCV Infection	-	-
Copegus	Phase 2	Hepatitis C, Chronic	-	-
N-acetylcysteine	Phase 2	Idiopathic Pulmonary Fibrosis	-	-
OpRegen	Phase 2	Age-Related Macular Degeneration	-	-
RO7795081	Phase 2	Obesity or Overweight	-	-
P38 Inhibitor (4) 150mg	Phase 2	Rheumatoid Arthritis	-	-
Experimental	Phase 2	Diabetic Neuropathy	-	-
Investigator's choice of anti-cancer treatment (except immunotherapy)	Phase 2	Breast Cancer	-	-
Trastuzumab emtansine [Kadcyla]	Phase 2	Breast Cancer	-	-
Taxane (docetaxel or paclitaxel)	Phase 2	Breast Cancer	-	-
RO5190591	Phase 2	Hepatitis C, Chronic	-	-
Temozolomide (TMZ)	Phase 2	High Grade Glioma	-	-
Sildenafil	Phase 2	Idiopathic Pulmonary Fibrosis	-	-
RAR Gamma	Phase 2	Emphysema	-	-
Ribociclib	Phase 2	Breast Cancer	-	-
Ocrelizumab Test Formulation	Phase 2	Multiple Sclerosis	-	-
Xeloda	Phase 2	Breast Cancer	-	-
C.E.R.A.	Phase 2	Anemia	-	-
cetuximab	Phase 2	Multiple Myeloma, Neoplasms	-	-
Mosunetuzumab (IV)	Phase 2	B-cell Non-Hodgkin Lymphoma	-	-
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg	Phase 2	Metastatic Breast Cancer	-	-
Didanosine	Phase 2	HIV Infections	-	-
Folinic Acid	Phase 2	Rectal Cancer	-	-
Autogene Cevumeran	Phase 2	Muscle-invasive Urothelial Carcinoma	-	-
Epothilone D	Phase 2	Breast Cancer	-	-
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)	Phase 2	HER2-Positive Early Breast Cancer	-	-
Interferon alfa-2a	Phase 2	Renal Cell Cancer	-	-
GK Activator (2)	Phase 2	Diabetes Mellitus Type 2	-	-
Atezolizumab (MPDL3280A) [TECENTRIQ]	Phase 2	Lymphoma, Follicular	-	-
DPP-IV Inhibitor	Phase 2	Diabetes Mellitus Type 2	-	-
SPK-8011QQ	Phase 2	Hemophilia A	-	-
PEGASYS [peginterferon alfa-2a]	Phase 2	Hepatitis B, Chronic	-	-
MSTT1041A	Phase 2	Asthma	-	-
RO7017773	Phase 2	Autism Spectrum Disorder (ASD)	-	-
RO 205-2349	Phase 2	Diabetes	-	-
Danoprevir	Phase 2	Hepatitis C, Chronic	-	-
RO5024048	Phase 2	Hepatitis C, Chronic	-	-
RO7247669	Phase 2	Melanoma	-	-
enfuvirtide [Fuzeon]	Phase 2	HIV Infections	-	-
Tiragolumab and Atezolizumab IV FDC	Phase 2	PD-L1-selected Solid Tumors	-	-
RG7314	Phase 2	Autism Spectrum Disorder	-	-
Tociliuzumab	Phase 2	COVID-19 Pneumonia	-	-
RO4998452	Phase 2	Diabetes Mellitus Type 2	-	-
AT-527	Phase 2	COVID-19	-	-
SGN-LIV1A	Phase 2	Metastatic Breast Cancer	-	-
FOLFOX induction regimen	Phase 2	Colorectal Cancer	-	-
First line chemotherapy	Phase 2	Mantle Cell Lymphoma	-	-
Mycophenolate Mofetil/Mycophenolic Acid	Phase 2	Lupus Nephritis	-	-
RO5313534	Phase 2	Alzheimer's Disease	-	-
Balovaptan	Phase 2	Stress Disorders, Post-Traumatic	-	-
Carboplatin-based chemotherapy	Phase 2	Non-Small Cell Lung Cancer	-	-
Pegylated Interferon (Peginterferon) Alfa-2a	Phase 2	Hepatitis B, Chronic	-	-
Lomvastomig	Phase 2	Advanced or Metastatic Esophageal Squamous Cell Carcinoma	-	-
Standard taxane therapy	Phase 2	Breast Cancer	-	-
Ifosfamide	Phase 2	Mature B-Cell Non-Hodgkin Lymphoma	-	-
GC33	Phase 2	Carcinoma, Hepatocellular	-	-
pralsetinib (BLU-667)	Phase 2	RET-altered Non Small Cell Lung Cancer	-	-
eloxatin	Phase 2	Colorectal Cancer	-	-
Inhaled corticposteroids (ICS)	Phase 2	Asthma	-	-
Optimized Background ARVs	Phase 2	HIV Infections	-	-
Abacavir sulfate	Phase 2	HIV Infections	-	-
RO5459072	Phase 2	Sjogren's Syndrome	-	-
Alogabat	Phase 2	Angelman Syndrome	-	-
89Zr-Df-IAB22M2C	Phase 2	Non-Hodgkins Lymphoma	-	-
RO5185426	Phase 2	Malignant Melanoma	-	-
Mosunetuzumab Intravenous (IV)	Phase 2	Diffuse Large B-cell Lymphoma	-	-
RO7269162	Phase 2	Alzheimer's Disease	-	-
Taspoglutide 20mg	Phase 2	Diabetes Mellitus Type 2	-	-
RO6958688	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody	Phase 2	Breast Neoplasms	-	-
RO4929097	Phase 2	Non-Squamous Non-Small Cell Lung Cancer	-	-
Levofolinic acid	Phase 2	Colorectal Cancer	-	-
Second line chemotherapy	Phase 2	Breast Cancer	-	-
Fulvestrant or an Aromatase Inhibitor (Physician Choice)	Phase 2	Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	-	-
RO7046015	Phase 2	Parkinson's Disease	-	-
Aromatase Inhibitor	Phase 2	Breast Cancer	-	-
Diphenhydramine hydrochloride (HCl)	Phase 2	Lupus Nephritis	-	-
Hormonal Therapy	Phase 2	Breast Cancer	-	-
Semaglutide	Phase 2	Type 2 Diabetes Mellitus	-	-
Tobemstomig	Phase 2	Urothelial Cancer	-	-
LABA	Phase 2	Asthma	-	-
PEGPH20	Phase 2	Pancreatic Adenocarcinoma	-	-
FOLFIRI	Phase 2	Colorectal Cancer	-	-
RO4602522	Phase 2	Alzheimer's Disease	-	-
Zifibancimig	Phase 2	Macular Degeneration	-	-
capecitabine (Xeloda®)	Phase 2	Breast Cancer	-	-
Standard platinum-based chemotherapy	Phase 2	Non-Small Cell Lung Cancer	-	-
bevacizumab (Avastin)	Phase 2	Liver Cancer	-	-
Epidoxorubicin	Phase 2	Breast Cancer	-	-
Pravastatin	Phase 2	Dyslipidemia	-	-
RG3421 120mg	Phase 2	Psoriasis	-	-
5-FU	Phase 2	Colorectal Cancer	-	-
Basmisanil	Phase 2	Schizophrenia	-	-
RG7774	Phase 2	Diabetic Retinopathy	-	-
Atezolizumab [TECENTRIQ]	Phase 2	Lymphoma	-	-
NXT007	Phase 2	Hemophilia A	-	-
beta-lactam	Phase 2	Soft Tissue Infections	-	-
Rituxumab	Phase 2	B-cell Non-Hodgkin Lymphoma	-	-
Polatuzumab vedotin (Liquid)	Phase 2	Lymphoma	-	-
RO7247669 2100 mg	Phase 2	Melanoma	-	-
Axitinib	Phase 2	Renal Cell Carcinoma	-	-
Rituximab IV	Phase 2	Lymphoma, Large B-Cell, Diffuse	-	-
Bevacizumab 15 mg/kg	Phase 2	Advanced Liver Cancers	-	-
TCS Cream	Phase 2	Atopic Dermatitis	-	-
vismodegib	Phase 2	Basal Cell Carcinoma	-	-
Anastrozole	Phase 2	Early Breast Cancer	-	-
Lomustine	Phase 2	Glioblastoma	-	-
Olesoxime (TRO19622)	Phase 2	Chemotherapy-Induced Peripheral Neuropathy	-	-
RO7126209	Phase 2	Alzheimers Disease	-	-
Metronidazole Actavis	Phase 2	Non-Squamous Non-Small Cell Lung Cancer	-	-
Tominersen	Phase 2	Huntington Disease	-	-
RO6889450	Phase 2	Schizophrenia, Schizoaffective Disorder	-	-
fluorouracil (5FU)	Phase 2	Colorectal Cancer	-	-
RO4917523 0.5 mg	Phase 2	Fragile X Syndrome	-	-
RO5190591 (Danoprevir)	Phase 2	Hepatitis C, Chronic	-	-
RO4905417	Phase 2	Coronary Heart Disease, Graft Occlusion, Vascular	-	-
SSRI	Phase 2	Obsessive-Compulsive Disorder	-	-
P38 Inhibitor (4)	Phase 2	Rheumatoid Arthritis	-	-
Ceftriaxone	Phase 2	Pneumonia, Bacterial	-	-
danoprevir + ritonavir	Phase 2	Hepatitis C, Chronic	-	-
Nucleos(t)ide (NUC)	Phase 2	Hepatitis B, Chronic	-	-
ribavirin [Copegus]	Phase 2	Hepatitis C, Chronic	-	-
Folic Acid	Phase 2	Rheumatoid Arthritis	-	-
Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)	Phase 2	Atopic Dermatitis	-	-
RO4917523	Phase 2	Fragile X Syndrome	-	-
Erlotinib, escalating dose	Phase 2	Pancreatic Cancer	-	-
RO4995819	Phase 2	Major Depressive Disorder	-	-
Englumafusp alfa	Phase 2	Lymphoma, Non-Hodgkin	-	-
ZN-A-1041	Phase 2	Advanced Solid Tumors	-	-
PRM-151	Phase 2	Idiopathic Pulmonary Fibrosis	-	-
RO7490677	Phase 2	Primary Myelofibrosis	-	-
RO5083945	Phase 2	Non-Squamous Non-Small Cell Lung Cancer	-	-
RO5217790	Phase 2	Cervical Intraepithelial Neoplasia	-	-
TRO40303	Phase 2	Acute Myocardial Infarctus	-	-
fotemustine	Phase 2	Glioblastoma Multiforme	-	-
Enfortumab Vedotin	Phase 2	Urothelial Carcinoma	-	-
Forimtamig	Phase 2	Relapsed or Refractory Multiple Myeloma	-	-
Induction- PF-06480605 50 mg SC Q4W	Phase 2	Moderate to Severe Ulcerative Colitis	-	-
Everolimus	Phase 2	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	-	-
RO5027838	Phase 2	Diabetes Mellitus Type 2	-	-
Sham Procedure	Phase 2	Neovascularization, Choroidal	-	-
RG1662	Phase 2	Down Syndrome	-	-
Abiraterone	Phase 2	Metastatic Castration-Resistant Prostate Cancer	-	-

Breast Cancer

1 drug in this indication

Duchenne Muscular Dystrophy

1 drug in this indication

Obesity

1 drug in this indication

Myasthenia Gravis Generalised

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Roche Holding AG

Market Overview

RHHBY News

Catalyst Timeline

Pipeline & FDA Submissions

Competitive Positions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals